

Steven P Treon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/666718/publications.pdf>

Version: 2024-02-01

333
papers

19,630
citations

11651

70
h-index

12946

131
g-index

336
all docs

336
docs citations

336
times ranked

9388
citing authors

#	ARTICLE	IF	CITATIONS
1	Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy. <i>Haematologica</i> , 2022, 107, 1163-1171.	3.5	11
2	Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. <i>Leukemia</i> , 2022, 36, 532-539.	7.2	50
3	Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNOVATE Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 52-62.	1.6	62
4	Venetoclax in Previously Treated Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 63-71.	1.6	53
5	Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia. <i>Blood Advances</i> , 2022, 6, 2230-2235.	5.2	10
6	Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy. <i>Blood Advances</i> , 2022, 6, 1015-1024.	5.2	12
7	SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 547-556.	0.4	6
8	High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia. <i>Blood Advances</i> , 2022, 6, 3655-3658.	5.2	4
9	Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac104.	0.9	6
10	A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. <i>Blood Advances</i> , 2022, 6, 3332-3338.	5.2	4
11	Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia. <i>Expert Review of Anticancer Therapy</i> , 2022, , .	2.4	3
12	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	1.4	512
13	Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for Waldenström macroglobulinemia (WM): An international collaborative study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7566-7566.	1.6	9
14	A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib. <i>EJHaem</i> , 2022, 3, 927-929.	1.0	1
15	Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib. <i>British Journal of Haematology</i> , 2021, 192, 542-550.	2.5	8
16	CXCR4 in Waldenström's Macroglobulinemia: chances and challenges. <i>Leukemia</i> , 2021, 35, 333-345.	7.2	53
17	Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 565-575.	1.6	98
18	Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition. <i>Epigenomics</i> , 2021, 13, 129-144.	2.1	7

#	ARTICLE	IF	CITATIONS
19	Clinical application of genomics in Waldenström macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1805-1815.	1.3	3
20	Reducing treatment toxicity in Waldenström macroglobulinemia. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-8.	2.4	2
21	Bone marrow involvement and subclonal diversity impairs detection of mutated <i>CXCR4</i> by diagnostic next-generation sequencing in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2021, 194, 730-733.	2.5	16
22	Cell-free DNA analysis for detection of <i>MYD88</i> ^{L265P} and <i>CXCR4</i> ^{S338X} mutations in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021, 96, E250-E253.	4.1	8
23	The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTK ^{Cys481} ibrutinib resistance. <i>Blood</i> , 2021, 138, 1966-1979.	1.4	16
24	Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. <i>Blood</i> , 2021, 138, 2002-2005.	1.4	27
25	Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia. <i>Blood</i> , 2021, 138, 1535-1539.	1.4	32
26	Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia. <i>HemaSphere</i> , 2021, 5, e624.	2.7	15
27	How to Sequence Therapies in Waldenström Macroglobulinemia. <i>Current Treatment Options in Oncology</i> , 2021, 22, 92.	3.0	5
28	Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate™ Trial. <i>Clinical Cancer Research</i> , 2021, 27, 5793-5800.	7.0	20
29	Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib. <i>British Journal of Haematology</i> , 2021, 195, 466-468.	2.5	2
30	A prognostic index predicting survival in transformed Waldenström macroglobulinemia. <i>Haematologica</i> , 2021, 106, 2940-2946.	3.5	11
31	IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM. <i>Blood</i> , 2021, 138, 1980-1985.	1.4	11
32	Preliminary Clinical Response Data from a Phase 1b Study of Mavoxifafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with <i>MYD88</i> and <i>CXCR4</i> Mutations. <i>Blood</i> , 2021, 138, 1362-1362.	1.4	8
33	Cleavage-Mediated Regulation of Myd88 Signaling by Inflammasome-Activated Caspase-1. <i>Frontiers in Immunology</i> , 2021, 12, 790258.	4.8	3
34	Deepening of response after completing rituximab-containing therapy in patients with Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 372-378.	4.1	6
35	Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. <i>HemaSphere</i> , 2020, 4, e433.	2.7	11
36	Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. <i>Lancet Haematology</i> , the, 2020, 7, e827-e837.	4.6	96

#	ARTICLE	IF	CITATIONS
37	Comparative genomics of CXCR4MUT and CXCR4WT single cells in Waldenström's macroglobulinemia. <i>Blood Advances</i> , 2020, 4, 4550-4553.	5.2	3
38	Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials. <i>HemaSphere</i> , 2020, 4, e363.	2.7	12
39	Management of Waldenström macroglobulinemia in 2020. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 372-379.	2.5	24
40	Epigenomics in Waldenström macroglobulinemia. <i>Blood</i> , 2020, 136, 527-529.	1.4	5
41	Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up. <i>Blood Advances</i> , 2020, 4, 3952-3959.	5.2	35
42	The race to stymie BTK: zanu zings. <i>Blood</i> , 2020, 136, 1997-1999.	1.4	7
43	The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19 infected patients. <i>Blood</i> , 2020, 135, 1912-1915.	1.4	253
44	Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. <i>Journal of Clinical Oncology</i> , 2020, 38, 1198-1208.	1.6	103
45	Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2020, 189, 1165-1170.	2.5	23
46	CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors. <i>American Journal of Hematology</i> , 2020, 95, E95-E98.	4.1	12
47	A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 1388-1394.	1.3	9
48	SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. <i>Blood Cancer Journal</i> , 2020, 10, 12.	6.2	34
49	Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas. <i>Blood Advances</i> , 2020, 4, 141-153.	5.2	13
50	Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATETM Trial. <i>Blood</i> , 2020, 136, 38-39.	1.4	7
51	Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATETM Study. <i>Blood</i> , 2020, 136, 24-26.	1.4	19
52	Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2019, 25, 369-377.	7.0	24
53	CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review. <i>Expert Review of Hematology</i> , 2019, 12, 873-881.	2.2	29
54	How we manage Bing-Neel syndrome. <i>British Journal of Haematology</i> , 2019, 187, 277-285.	2.5	45

#	ARTICLE	IF	CITATIONS
55	<i>CXCR4</i> mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib. <i>British Journal of Haematology</i> , 2019, 187, 356-363.	2.5	73
56	What is new in the treatment of Waldenstrom macroglobulinemia?. <i>Leukemia</i> , 2019, 33, 2555-2562.	7.2	19
57	Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 1403-1411.	1.6	65
58	Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells. <i>Blood Advances</i> , 2019, 3, 3360-3374.	5.2	25
59	<i>CXCR4</i> S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia. <i>Blood Advances</i> , 2019, 3, 2800-2803.	5.2	27
60	Genomic landscape of Waldenström's macroglobulinemia. <i>HemaSphere</i> , 2019, 3, 58-61.	2.7	1
61	Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e39-e40.	0.4	9
62	<i>TP53</i> mutations are associated with mutated <i>MYD88</i> and <i>CXCR4</i> , and confer an adverse outcome in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2019, 184, 242-245.	2.5	33
63	Long survival in patients with Waldenström macroglobulinaemia diagnosed at a young age. <i>British Journal of Haematology</i> , 2019, 185, 799-802.	2.5	4
64	Low risk of <i>Pneumocystis jirovecii</i> pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib. <i>British Journal of Haematology</i> , 2019, 185, 788-790.	2.5	12
65	Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. <i>British Journal of Haematology</i> , 2019, 184, 558-569.	2.5	71
66	Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. <i>Blood</i> , 2019, 133, 299-305.	1.4	69
67	Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2019, 184, 1011-1014.	2.5	19
68	Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2018, 181, 77-85.	2.5	41
69	BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism. <i>Blood</i> , 2018, 131, 2047-2059.	1.4	61
70	Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2018, 24, 3247-3252.	7.0	57
71	Waldenström's Macroglobulinemia. <i>Hematologic Malignancies</i> , 2018, , 191-220.	0.2	2
72	Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2018, 4, 744.	7.1	0

#	ARTICLE	IF	CITATIONS
73	Extracellular vesicle-mediated transfer of constitutively active MyD88L265P engages MyD88wt and activates signaling. <i>Blood</i> , 2018, 131, 1720-1729.	1.4	36
74	Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound. <i>American Journal of Hematology</i> , 2018, 93, 511-517.	4.1	61
75	Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia. <i>Haematologica</i> , 2018, 103, e307-e310.	3.5	45
76	MYD88 mutated and wild-type Waldenström Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4. <i>Haematologica</i> , 2018, 103, e408-e411.	3.5	30
77	MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2018, 180, 578-581.	2.5	19
78	MYD88 wild-type Waldenström Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. <i>British Journal of Haematology</i> , 2018, 180, 374-380.	2.5	83
79	Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenström's macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, E69-E71.	4.1	1
80	A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degradator. <i>Cell Chemical Biology</i> , 2018, 25, 88-99.e6.	5.2	313
81	Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 2755-2761.	1.6	142
82	Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia. <i>PLoS ONE</i> , 2018, 13, e0204589.	2.5	17
83	Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenström macroglobulinemia patients. <i>Blood</i> , 2018, 132, 2608-2612.	1.4	29
84	Waldenström Macroglobulinemia: Lessons Learned from Basic and Clinical Research. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, xiii-xiv.	2.2	0
85	Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström Macroglobulinemia. <i>New England Journal of Medicine</i> , 2018, 378, 2399-2410.	27.0	291
86	Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, E201.	4.1	1
87	The real world of Waldenström's macroglobulinaemia. <i>Lancet Haematology</i> , 2018, 5, e275-e276.	4.6	2
88	Initial Evaluation of the Patient with Waldenström Macroglobulinemia. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 811-820.	2.2	16
89	Genomic Landscape of Waldenström Macroglobulinemia. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 745-752.	2.2	16
90	Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma. , 2018, , 1419-1431.e5.		0

#	ARTICLE	IF	CITATIONS
91	Waldenstrom's Macroglobulinemia. , 2018, , 617-638.		0
92	Targeting Myddosome Signaling in Waldenstrom's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. <i>Clinical Cancer Research</i> , 2018, 24, 6408-6420.	7.0	15
93	Ibrutinib Treatment in Waldenstrom's Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATE TM Study. <i>Blood</i> , 2018, 132, 149-149.	1.4	20
94	Non-IgM Secreting Lymphoplasmacytic Lymphoma - Experience of a Reference Center for Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 2886-2886.	1.4	9
95	A Novel HCK Inhibitor Kin-8193 Blocks BTK Activity in BTK ^{Cys481} Mutated Ibrutinib Resistant B-Cell Lymphomas Driven By Mutated MYD88. <i>Blood</i> , 2018, 132, 40-40.	1.4	9
96	Alternative Mutations and Isoform Dysregulation in MYD88 in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2018, 132, 1566-1566.	1.4	4
97	Insights into the genomic landscape of MYD88 wild-type Waldenstrom macroglobulinemia. <i>Blood Advances</i> , 2018, 2, 2937-2946.	5.2	72
98	Triple Degradation of BTK, IKZF1 and IKZF3 in B-Cell Malignancies. <i>Blood</i> , 2018, 132, 263-263.	1.4	0
99	Acquired mutations associated with ibrutinib resistance in Waldenstrom macroglobulinemia. <i>Blood</i> , 2017, 129, 2519-2525.	1.4	115
100	Investigation and management of IgM and Waldenstrom's associated peripheral neuropathies: recommendations from the IWWM consensus panel. <i>British Journal of Haematology</i> , 2017, 176, 728-742.	2.5	58
101	Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenstrom macroglobulinaemia. <i>British Journal of Haematology</i> , 2017, 177, 717-725.	2.5	58
102	Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. <i>Oncology</i> , 2017, 6, e1321184.	4.6	23
103	Novel approaches to targeting MYD88 in Waldenstrom macroglobulinemia. <i>Expert Review of Hematology</i> , 2017, 10, 739-744.	2.2	6
104	Ibrutinib for patients with rituximab-refractory Waldenstrom's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2017, 18, 241-250.	10.7	212
105	Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. <i>Haematologica</i> , 2017, 102, 43-51.	3.5	112
106	Comparative outcomes of immunochemotherapy regimens in Waldenstrom macroglobulinaemia. <i>British Journal of Haematology</i> , 2017, 179, 106-115.	2.5	14
107	CXCL13 levels are elevated in patients with Waldenstrom macroglobulinemia, and are predictive of major response to ibrutinib. <i>Haematologica</i> , 2017, 102, e452-e455.	3.5	22
108	To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenstrom Macroglobulinaemia. <i>British Journal of Haematology</i> , 2017, 176, 822-824.	2.5	22

#	ARTICLE	IF	CITATIONS
109	Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia. British Journal of Haematology, 2017, 177, 808-813.	2.5	13
110	Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome. British Journal of Haematology, 2017, 179, 339-341.	2.5	56
111	Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity. Leukemia and Lymphoma, 2017, 58, 1002-1004.	1.3	31
112	Signal Inhibitors in Waldenström's Macroglobulinemia. , 2017, , 327-334.		0
113	Immunomodulatory Agents and Proteasome Inhibitors in Waldenström's Macroglobulinemia. , 2017, , 335-343.		0
114	Treatment Recommendations in Waldenström Macroglobulinemia. , 2017, , 367-370.		1
115	Genetic and Signaling Abnormalities in Waldenström's Macroglobulinemia. , 2017, , 53-65.		1
116	Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Clinical Cancer Research, 2017, 23, 2400-2404.	7.0	23
117	Toward personalized treatment in Waldenström macroglobulinemia. Hematology American Society of Hematology Education Program, 2017, 2017, 365-370.	2.5	7
118	Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia. Journal of Clinical Oncology, 2017, 35, 994-1001.	1.6	76
119	What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy. Blood Advances, 2017, 1, 2486-2490.	5.2	5
120	The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions. Oncotarget, 2017, 8, 35435-35444.	1.8	4
121	12. Waldenström's macroglobulinemia. , 2016, , 229-244.		0
122	Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders. Cancer Journal (Sudbury, Mass), 2016, 22, 34-39.	2.0	25
123	Central nervous system involvement by Waldenström macroglobulinaemia (Bing's Neel syndrome): a multi-institutional retrospective study. British Journal of Haematology, 2016, 172, 709-715.	2.5	87
124	Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. Blood, 2016, 127, 2598-2606.	1.4	22
125	Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. Blood, 2016, 128, 827-838.	1.4	91
126	Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood, 2016, 128, 1321-1328.	1.4	161

#	ARTICLE	IF	CITATIONS
127	Epigenomics in Waldenstrom's macroglobulinaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 156-160.	1.7	1
128	Future therapeutic options for patients with Waldenström macroglobulinemia. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 206-215.	1.7	4
129	Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis. <i>Oncologist</i> , 2016, 21, 1377-1386.	3.7	36
130	Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2016, 91, 1032-1035.	4.1	53
131	Rituximab intolerance in patients with Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2016, 174, 645-648.	2.5	34
132	Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes. <i>British Journal of Haematology</i> , 2016, 175, 623-630.	2.5	68
133	HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. <i>Blood</i> , 2016, 127, 3237-3252.	1.4	93
134	Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , 2016, 175, 77-86.	2.5	61
135	Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 179-186.	2.5	28
136	Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. <i>Clinical Cancer Research</i> , 2016, 22, 6099-6109.	7.0	19
137	Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2016, 91, E312-3.	4.1	52
138	Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , 2016, 172, 735-744.	2.5	122
139	Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells. <i>Clinical Cancer Research</i> , 2016, 22, 2226-2236.	7.0	26
140	Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. <i>Leukemia and Lymphoma</i> , 2016, 57, 2699-2701.	1.3	4
141	Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenstrom macroglobulinemia. <i>Haematologica</i> , 2016, 101, e111-e115.	3.5	30
142	Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2016, 128, 2984-2984.	1.4	8
143	The BCL2 antagonist ABT199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 ^{hi} and CXCR4 ^{lo} WHIM ⁺ mutated Waldenstrom macroglobulinaemia cells. <i>British Journal of Haematology</i> . 2015. 170. 134-138.	2.5	63
144	Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database. <i>Cancer</i> , 2015, 121, 2230-2236.	4.1	33

#	ARTICLE	IF	CITATIONS
145	The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. <i>Nature Medicine</i> , 2015, 21, 572-580.	30.7	79
146	How I treat Waldenström macroglobulinemia. <i>Blood</i> , 2015, 126, 721-732.	1.4	165
147	Biology, Prognosis, and Therapy of Waldenström Macroglobulinemia. <i>Cancer Treatment and Research</i> , 2015, 165, 177-195.	0.5	17
148	Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia. <i>American Journal of Hematology</i> , 2015, 90, E122-3.	4.1	13
149	Extramedullary Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2015, 90, 100-104.	4.1	47
150	Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2015, 21, 2538-2545.	7.0	19
151	Ibrutinib in Previously Treated Waldenström's Macroglobulinemia. <i>New England Journal of Medicine</i> , 2015, 372, 1430-1440.	27.0	810
152	CXCR4 and WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88-L265P-directed survival signalling in Waldenström macroglobulinaemia cells. <i>British Journal of Haematology</i> , 2015, 168, 701-707.	2.5	95
153	Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. <i>British Journal of Haematology</i> , 2015, 169, 81-89.	2.5	110
154	MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia. <i>New England Journal of Medicine</i> , 2015, 373, 584-586.	27.0	212
155	Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2015, 126, 1833-1833.	1.4	23
156	Targeting IRAK1/IRAK4 Signaling in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2015, 126, 4004-4004.	1.4	11
157	Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. <i>American Journal of Hematology</i> , 2014, 89, 237-242.	4.1	68
158	Transcriptional repression of plasma cell differentiation is orchestrated by aberrant over-expression of the ETS factor SPIB in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2014, 166, 677-689.	2.5	16
159	The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. <i>Blood</i> , 2014, 123, 1637-1646.	1.4	394
160	MYD88-independent growth and survival effects of Sp1 transactivation in Waldenström macroglobulinemia. <i>Blood</i> , 2014, 123, 2673-2681.	1.4	16
161	Waldenström macroglobulinemia: from biology to treatment. <i>Expert Review of Hematology</i> , 2014, 7, 157-168.	2.2	16
162	Waldenström Macroglobulinemia. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 945-970.	2.2	21

#	ARTICLE	IF	CITATIONS
163	Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia. <i>Blood</i> , 2014, 123, 2791-2796.	1.4	337
164	Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. <i>Blood</i> , 2014, 124, 1404-1411.	1.4	138
165	Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. <i>Blood</i> , 2014, 124, 503-510.	1.4	168
166	Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. <i>Blood</i> , 2014, 123, 3999-4000.	1.4	91
167	Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenström Macroglobulinemia (WM). <i>Blood</i> , 2014, 124, 1715-1715.	1.4	28
168	Waldenström's Macroglobulinemia. , 2014, , 303-329.		0
169	Bing-Neel Syndrome: A Rare Complication of Waldenström's Macroglobulinemia. <i>Blood</i> , 2014, 124, 5480-5480.	1.4	0
170	Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenström Macroglobulinemia. <i>Blood</i> , 2014, 124, 2070-2070.	1.4	0
171	XIII. Waldenström's macroglobulinaemia: an indolent B-cell lymphoma with distinct molecular and clinical features. <i>Hematological Oncology</i> , 2013, 31, 76-80.	1.7	13
172	microRNA Aberrations in Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 205-207.	0.4	14
173	Response assessment in Waldenström macroglobulinaemia: update from the International Workshop. <i>British Journal of Haematology</i> , 2013, 160, 171-176.	2.5	226
174	Patients With Waldenström Macroglobulinemia Commonly Present With Iron Deficiency and Those With Severely Depressed Transferrin Saturation Levels Show Response to Parenteral Iron Administration. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 241-243.	0.4	17
175	Comparative Response Assessment by Serum Immunoglobulin M M-Protein and Total Serum Immunoglobulin M After Treatment of Patients With Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 250-252.	0.4	9
176	MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. <i>Blood</i> , 2013, 121, 2051-2058.	1.4	368
177	Proteasome inhibitors in Waldenström macroglobulinemia. <i>Blood</i> , 2013, 122, 3243-3244.	1.4	13
178	A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. <i>Blood</i> , 2013, 122, 1222-1232.	1.4	306
179	A new era for Waldenström macroglobulinemia: MYD88 L265P. <i>Blood</i> , 2013, 121, 4434-4436.	1.4	50
180	Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma. , 2013, , 83-109.		0

#	ARTICLE	IF	CITATIONS
181	Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1211-1219.	4.9	38
182	Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: A preliminary study. Cancer Epidemiology, 2012, 36, 294-297.	1.9	13
183	Familial Disease Predisposition Impacts Treatment Outcome in Patients With Waldenström Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 433-437.	0.4	24
184	MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia. New England Journal of Medicine, 2012, 367, 826-833.	27.0	1,142
185	Inhibition of Spleen Tyrosine Kinase with Fostamatinib Shows Pre-Clinical Activity Against Models of Waldenström Macroglobulinemia. Blood, 2012, 120, 3723-3723.	1.4	0
186	MYD88 L265P Promotes Survival of Waldenstrom's Macroglobulinemia Cells by Activation of Bruton's Tyrosine Kinase. Blood, 2012, 120, 897-897.	1.4	1
187	Associated Malignancies in Patients with Waldenström's Macroglobulinemia and Their Kin. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 88-92.	0.4	35
188	Bendamustine Therapy in Patients With Relapsed or Refractory Waldenström's Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 133-135.	0.4	101
189	Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenström's Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 152-156.	0.4	22
190	Hepcidin Is Produced by Lymphoplasmacytic Cells and Is Associated With Anemia in Waldenström's Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 160-163.	0.4	33
191	Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells. Leukemia and Lymphoma, 2011, 52, 1777-1786.	1.3	9
192	Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen. British Journal of Haematology, 2011, 154, 357-362.	2.5	92
193	Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood, 2011, 118, 276-281.	1.4	42
194	Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in <i>FCGR3A</i> in Waldenstrom macroglobulinaemia. British Journal of Haematology, 2011, 154, 223-228.	2.5	61
195	Treatment with a Bortezomib-Containing Regimen Is Associated with Better Therapeutic Outcomes in Patients with Waldenstrom's Macroglobulinemia Who Have Familial Disease Predisposition. Blood, 2011, 118, 1643-1643.	1.4	3
196	A Somatic Variant in MYD88 (L265P) Revealed by Whole Genome Sequencing Differentiates Lymphoplasmacytic Lymphoma From Marginal Zone Lymphomas. Blood, 2011, 118, 261-261.	1.4	8
197	Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia. Blood, 2011, 118, 2705-2705.	1.4	1
198	Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia. Blood, 2011, 118, 2951-2951.	1.4	17

#	ARTICLE	IF	CITATIONS
199	Whole Genome Sequencing Reveals a Widely Expressed Mutation (MYD88 L265P) with Oncogenic Activity in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2011, 118, 300-300.	1.4	15
200	Incidence of Peripheral Neuropathy in Waldenstrom's Macroglobulinemia Patients At Diagnosis. <i>Blood</i> , 2011, 118, 3692-3692.	1.4	3
201	Whole-Genome Sequencing Results From 30 Patients with Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2011, 118, 434-434.	1.4	5
202	Disruption of MYD88 Pathway Signaling Leads to Loss of Constitutive IRAK1, NF- κ B and JAK/STAT Signaling and Induces Apoptosis of Cells Expressing the MYD88 L265P Mutation in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2011, 118, 597-597.	1.4	1
203	Aberrant Expression of Oct-2, Spi-B, and Id2/Id1 Is Associated with Repression of Plasma Cell Differentiation in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2011, 118, 86-86.	1.4	0
204	Targeting Bruton's Tyrosine Kinase with PCI-32765 Blocks Growth and Survival of Multiple Myeloma and Waldenstrom's Macroglobulinemia Via Potent Inhibition of Osteoclastogenesis, Cytokines/Chemokine Secretion, and Myeloma Stem-Like Cells in the Bone Marrow Microenvironment. <i>Blood</i> , 2011, 118, 883-883.	1.4	1
205	The Role of Bortezomib-Containing Regimens in Improving Response in Patients with Waldenstrom Macroglobulinemia. <i>Blood</i> , 2011, 118, 2713-2713.	1.4	0
206	MicroRNA-21 and μ 155 Are Induced by a Widely Expressed Mutation in MyD88 (L265P) in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2011, 118, 3957-3957.	1.4	0
207	IgA and IgG hypogammaglobulinemia in Waldenstrom's macroglobulinemia. <i>Haematologica</i> , 2010, 95, 470-475.	3.5	53
208	Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom's Macroglobulinemia. <i>American Journal of Hematology</i> , 2010, 85, 670-674.	4.1	138
209	Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenstrom's Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1408-1414.	1.6	132
210	Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1422-1428.	1.6	150
211	Bortezomib as a Treatment Option in Patients With Waldenstrom's Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 110-117.	0.4	20
212	Fc γ 3 Receptor Predictive Genomic Testing and the Treatment of Indolent Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 321-322.	0.4	6
213	The Rituximab and IVIG Related IgM Flare In Waldenstrom's Macroglobulinemia Is Associated with Monocytic Activation of Fc γ 1a Signaling, and Triggering of IL-6 Release by the PI3K/AKT and MAPK Pathways. <i>Blood</i> , 2010, 116, 2870-2870.	1.4	4
214	Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , 2010, 116, 3952-3952.	1.4	9
215	The Anti-CD20 Monoclonal Antibody GA101 Displays More Robust Anti-Tumor Activity Versus Rituximab In Waldenstrom's Macroglobulinemia (WM). <i>Blood</i> , 2010, 116, 4904-4904.	1.4	1
216	MLN4924, a Novel Investigational NEDD8 Activating Enzyme Inhibitor, Exhibits Preclinical Activity In Multiple Myeloma and Waldenstrom's Macroglobulinemia through Mechanism Distinct From Existing Proteasome Inhibitors. <i>Blood</i> , 2010, 116, 2988-2988.	1.4	2

#	ARTICLE	IF	CITATIONS
217	Aberrant Expression of Regulatory miRNAs and Transcripts for IRS-PI3K Growth and Survival Signaling In Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2010, 116, 1912-1912.	1.4	2
218	Bone Marrow Niche Down-Regulates Mir-30 In Multiple Myeloma Cells to Promote Cancer Progression and Cancer Initiation by Targeting BCL9/Wnt Pathway.. <i>Blood</i> , 2010, 116, 1569-1569.	1.4	0
219	Interleukin-17 and TH17 Pathway Supports Waldenstrom's Macroglobulinemia Cell-Growth: Potential Therapeutic Implications. <i>Blood</i> , 2010, 116, 446-446.	1.4	11
220	Involvement of Lipogenic Pathway In 5-Azacytidine-Induced Cytotoxicity In Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2010, 116, 2991-2991.	1.4	0
221	Bendamustine-Based Therapy Is Highly Active In Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2010, 116, 4700-4700.	1.4	15
222	Targeting Sp1 Transactivation In Waldenstrom's Macroglobulinemia: a Novel Therapeutic Option. <i>Blood</i> , 2010, 116, 120-120.	1.4	0
223	Involvement of Ets Factor Spi-B and Id2 In Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2010, 116, 129-129.	1.4	22
224	Microarray Analysis of the Peripheral Monocytes From Waldenstrom's Macroglobulinemia Patients Reveals a Distinct Gene Expression Profile. <i>Blood</i> , 2010, 116, 2010-2010.	1.4	2
225	Associated Malignancies Among Patients and Kin with Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2010, 116, 4159-4159.	1.4	0
226	Comprehensive Assessment of Cytokines and Chemokines In Patients with Waldenstrom's Macroglobulinemia Reveals a Distinct Profile with Pathobiological and Clinical Relevance. <i>Blood</i> , 2010, 116, 1911-1911.	1.4	1
227	Update on Treatment Recommendations From the Fourth International Workshop on Waldenstrom's Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 120-126.	1.6	207
228	Increased Incidence of Transformation and Myelodysplasia/Acute Leukemia in Patients With Waldenstrom's Macroglobulinemia Treated With Nucleoside Analogs. <i>Journal of Clinical Oncology</i> , 2009, 27, 250-255.	1.6	170
229	Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia. <i>Clinical Cancer Research</i> , 2009, 15, 355-360.	7.0	124
230	Primary Therapy of Waldenstrom's Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180. <i>Journal of Clinical Oncology</i> , 2009, 27, 3830-3835.	1.6	265
231	Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. <i>British Journal of Haematology</i> , 2009, 145, 59-63.	2.5	17
232	Advances in the Biology and Treatment of Waldenstrom's Macroglobulinemia: A Report from the 5th International Workshop on Waldenstrom's Macroglobulinemia, Stockholm, Sweden. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 10-15.	1.4	11
233	Soluble CD27 Is a Faithful Marker of Disease Burden and Is Unaffected by the Rituximab-Induced IgM Flare, as Well as by Plasmapheresis, in Patients with Waldenstrom's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 56-58.	1.4	19
234	Comparative Outcomes Following CP-R, CVP-R, and CHOP-R in Waldenstrom's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 62-66.	1.4	63

#	ARTICLE	IF	CITATIONS
235	Balancing Risk Versus Benefit in the Treatment of Waldenström's Macroglobulinemia Patients with Nucleoside Analogue-Based Therapy. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 71-73.	1.4	40
236	Ophthalmologic Techniques to Assess the Severity of Hyperviscosity Syndrome and the Effect of Plasmapheresis in Patients with Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 100-103.	1.4	28
237	International prognostic scoring system for Waldenström macroglobulinemia. <i>Blood</i> , 2009, 113, 4163-4170.	1.4	366
238	Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. <i>Blood</i> , 2009, 113, 3673-3678.	1.4	141
239	Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. <i>Blood</i> , 2009, 113, 626-634.	1.4	20
240	How I treat Waldenström macroglobulinemia. <i>Blood</i> , 2009, 114, 2375-2385.	1.4	206
241	Maintenance Rituximab Is Associated with Improved Progression Free and Overall Survival in Waldenstrom's Macroglobulinemia.. <i>Blood</i> , 2009, 114, 3750-3750.	1.4	1
242	Gene Expression Profiling Distinguishes Waldenstrom's Macroglobulinemia Patients Presenting with Familial Disease, Advanced IPSS Prognostic Score, and Previous Treatment with Rituximab.. <i>Blood</i> , 2009, 114, 3930-3930.	1.4	1
243	The HMG-CoA inhibitor, simvastatin, triggers <i>in vitro</i> anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. <i>British Journal of Haematology</i> , 2008, 142, 775-785.	2.5	21
244	CD27-CD70 interactions in the pathogenesis of Waldenström macroglobulinemia. <i>Blood</i> , 2008, 112, 4683-4689.	1.4	74
245	Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenstrom's Macroglobulinemia. <i>Clinical Cancer Research</i> , 2008, 14, 1849-1858.	7.0	75
246	Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 1104-1107.	1.3	44
247	Targeting NF- κ B in Waldenstrom macroglobulinemia. <i>Blood</i> , 2008, 111, 5068-5077.	1.4	106
248	Dual targeting of the proteasome regulates survival and homing in Waldenström macroglobulinemia. <i>Blood</i> , 2008, 111, 4752-4763.	1.4	79
249	Thalidomide and rituximab in Waldenstrom macroglobulinemia. <i>Blood</i> , 2008, 112, 4452-4457.	1.4	135
250	Advances in the treatment of monoclonal gammopathies: The emerging role of targeted therapy in plasma cell dyscrasias. <i>Biologics: Targets and Therapy</i> , 2008, 2, 419.	3.2	3
251	Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.. <i>Blood</i> , 2008, 112, 1011-1011.	1.4	1
252	IgA and IgG Hypogammaglobulinemia Is a Constitutive Feature in Most Waldenstrom's Macroglobulinemia Patients and May Be Related to Mutations Associated with Common Variable Immunodeficiency Disorder (CVID). <i>Blood</i> , 2008, 112, 3749-3749.	1.4	5

#	ARTICLE	IF	CITATIONS
253	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , 2008, 112, 832-832.	1.4	7
254	Microna Expression Profile Identifies Distinct Clinically Relevant Sub-Groups in Multiple Myeloma: Novel Prognostic Markers and Potential Targets for Therapy. <i>Blood</i> , 2008, 112, 96-96.	1.4	2
255	Waldenstrom's Macroglobulinemia/ Lymphoplasmacytic Lymphoma. , 2008, 142, 211-242.		4
256	Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248. <i>Clinical Cancer Research</i> , 2007, 13, 3320-3325.	7.0	186
257	The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. <i>Blood</i> , 2007, 110, 4417-4426.	1.4	141
258	Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. <i>Blood</i> , 2007, 109, 4964-4972.	1.4	100
259	Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fcγ3RIIIa-158 V/V and V/F polymorphism. <i>Blood</i> , 2007, 110, 2561-2564.	1.4	244
260	Genetic Linkage of Fcγ3RIIIa and Fcγ3RIIIb and Implications for Their Use in Predicting Clinical Responses to CD20-Directed Monoclonal Antibody Therapy. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 286-290.	1.4	30
261	Novel Agents in the Treatment of Waldenstrom's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, S199-S206.	1.4	15
262	Hepatitis C viral infection is not associated with Waldenstrom's macroglobulinemia. <i>American Journal of Hematology</i> , 2007, 82, 83-84.	4.1	64
263	Establishment of BCWM.1 cell line for Waldenstrom's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. <i>Experimental Hematology</i> , 2007, 35, 1366-1375.	0.4	61
264	Serum Immunoglobulin Free Light Chain (sFLC) Is a Sensitive Marker of Response in Waldenstrom Macroglobulinemia (WM).. <i>Blood</i> , 2007, 110, 1486-1486.	1.4	1
265	The Combination of Bortezomib and NPI-0052 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia (WM).. <i>Blood</i> , 2007, 110, 1516-1516.	1.4	19
266	Comprehensive Molecular Characterization of Malignant and Microenvironmental Cells in Waldenstrom's Macroglobulinemia by Gene Expression Profiling.. <i>Blood</i> , 2007, 110, 3174-3174.	1.4	8
267	Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007, 110, 4493-4493.	1.4	1
268	Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007, 110, 4496-4496.	1.4	2
269	Role of CCL5 and Interleukin-6 in the Biology of Waldenstrom Macroglobulinemia.. <i>Blood</i> , 2007, 110, 688-688.	1.4	2
270	Targeting NF-κB by Perifosine, Bortezomib and Rituximab in Waldenstrom Macroglobulinemia (WM).. <i>Blood</i> , 2007, 110, 2512-2512.	1.4	0

#	ARTICLE	IF	CITATIONS
271	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. Blood, 2007, 110, 4494-4494.	1.4	1
272	Resveratrol Exerts Antiproliferative Effect and Induces Apoptosis in Waldenstrom's Macroglobulinemia.. Blood, 2007, 110, 1383-1383.	1.4	2
273	Update on Recommendations for Assessing Response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2006, 6, 380-383.	1.4	107
274	CD52 Is Expressed on Human Mast Cells and Is a Potential Therapeutic Target in Waldenstrom's Macroglobulinemia and Mast Cell Disorders. Clinical Lymphoma and Myeloma, 2006, 6, 478-483.	1.4	41
275	Heterogeneous CD52 Expression among Hematologic Neoplasms: Implications for the Use of Alemtuzumab (CAMPATH-1H). Clinical Cancer Research, 2006, 12, 7174-7179.	7.0	133
276	Hyperviscosity-Related Retinopathy in Waldenstrom Macroglobulinemia. JAMA Ophthalmology, 2006, 124, 1601.	2.4	94
277	Serum Free Light Chain in Waldenstrom Macroglobulinemia.. Blood, 2006, 108, 2420-2420.	1.4	11
278	Preclinical In Vitro and In Vivo Evidence Support a Therapeutic Role for the CD70 Directed Monoclonal Antibody (SGN-70) in Waldenstrom's Macroglobulinemia (WM).. Blood, 2006, 108, 2490-2490.	1.4	4
279	The Selective Protein Kinase CB Inhibitor, Enzastaurin, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom's Macroglobulinemia.. Blood, 2006, 108, 2496-2496.	1.4	2
280	Novel Agent Perifosine Enhances Antitumor Activity of Bortezomib, Rituximab and Other Conventional Therapies in Waldenstrom's Macroglobulinemia.. Blood, 2006, 108, 2517-2517.	1.4	3
281	Bortezomib, Dexamethasone and Rituximab (BDR) Is a Highly Active Regimen in the Primary Therapy of Waldenstrom's Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-180.. Blood, 2006, 108, 2765-2765.	1.4	10
282	Abnormalities in Lipoprotein Metabolism Provide Insight into Novel Therapeutic Approaches for Waldenstrom's Macroglobulinemia (WM).. Blood, 2006, 108, 4749-4749.	1.4	2
283	Molecular Mechanisms Regulating Resistance to the Akt Inhibitor Perifosine in Waldenstrom's Macroglobulinemia, the Role of the ERK and PKC Pathways.. Blood, 2006, 108, 2416-2416.	1.4	1
284	Imatinib Mesylate (Gleevec®) Is Active in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-140.. Blood, 2006, 108, 2484-2484.	1.4	2
285	The CXCR4/SDF-1 Axis Regulates Migration and Adhesion in Waldenstrom Macroglobulinemia.. Blood, 2006, 108, 2418-2418.	1.4	2
286	Perifosine, an Oral Bioactive Novel Akt Inhibitor, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom Macroglobulinemia.. Blood, 2006, 108, 2488-2488.	1.4	2
287	Molecular Characterization of Clonotypic VDJ Sequences in Waldenstrom's Macroglobulinemia Suggests Independent Transformation Events in the Development of Biclinal B Cells.. Blood, 2006, 108, 4624-4624.	1.4	0
288	Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. British Journal of Haematology, 2005, 128, 192-203.	2.5	305

#	ARTICLE	IF	CITATIONS
289	Polymorphisms in Fc γ RIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in Waldenström's Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 474-481.	1.6	263
290	Report of the Third International Workshop on Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2005, 5, 215-216.	2.1	22
291	CD5, CD10, and CD23 Expression in Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2005, 5, 246-249.	2.1	71
292	CHOP plus Rituximab Therapy in Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2005, 5, 273-277.	2.1	55
293	Diagnosis and Management of Waldenstrom's Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 1564-1577.	1.6	225
294	Phase II Study of CC-5013 (Revlimid) and Rituximab in Waldenstrom's Macroglobulinemia: Preliminary Safety and Efficacy Results.. <i>Blood</i> , 2005, 106, 2443-2443.	1.4	7
295	CD27-Mediated Apoptosis Is Dependent on Siva-Induced Caspase Activation in Human Multiple Myeloma.. <i>Blood</i> , 2005, 106, 3398-3398.	1.4	1
296	Establishment of a Waldenstrom's Macroglobulinemia Cell Line (BCWM.1) with Productive In Vivo Engraftment in SCID-hu Mice.. <i>Blood</i> , 2005, 106, 979-979.	1.4	5
297	Bone Marrow Mast Cells Are Significantly Increased in Patients with Waldenstrom's Macroglobulinemia, and Their Number Following Therapeutic Intervention Is Dependent on Extent of Response.. <i>Blood</i> , 2005, 106, 980-980.	1.4	3
298	Evaluation of CD52 Expression in Hematopoietic Neoplasms by Standard Immunohistochemistry: Implications for the Expanded Use of Alemtuzumab (CAMPATH-1H) in the Treatment of Hematological Malignancies.. <i>Blood</i> , 2005, 106, 3346-3346.	1.4	1
299	Polymorphisms in Fc γ RIIIA Are Genetically Linked to Fc γ RIIA and May Account for the Primary Predictive Role Ascribed to Polymorphisms in Fc γ RIIIA-158 in Determining Rituximab Responses.. <i>Blood</i> , 2005, 106, 2433-2433.	1.4	3
300	Proteomic Analysis of Waldenstrom Macroglobulinemia (WM) Using Nanoscale Protein Micorarray Techniques.. <i>Blood</i> , 2005, 106, 504-504.	1.4	0
301	Hepatitis C Viral Infection Is Not Associated with Waldenstrom's Macroglobulinemia.. <i>Blood</i> , 2005, 106, 4693-4693.	1.4	0
302	Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications.. <i>Blood</i> , 2005, 106, 5150-5150.	1.4	0
303	Sequence Analysis in the BLYS and APRIL Receptor TACI Reveals Novel Variants with a Potential Pathogenetic Role in Waldenstrom's Macroglobulinemia (WM).. <i>Blood</i> , 2005, 106, 991-991.	1.4	1
304	Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications. <i>Cancer Research</i> , 2004, 64, 2846-2852.	0.9	126
305	Clinical Responses to Sildenafil in Waldenstrom's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2004, 5, 205-207.	2.1	26
306	B-Lymphocyte Stimulator Protein (BLYS) Is Expressed by Bone Marrow Mast and Lymphoplasmacytic Cells in Waldenstrom's Macroglobulinemia, and Provides Signaling for Growth, Survival and IgM Secretion.. <i>Blood</i> , 2004, 104, 3358-3358.	1.4	13

#	ARTICLE	IF	CITATIONS
307	Clinical Responses to Sildenafil in Waldenstrom's Macroglobulinemia.. Blood, 2004, 104, 4926-4926.	1.4	1
308	Lymphoplasmacytic Cells and Mast Cells Are Targets for Imatinib Mesylate (Gleevec, Glivec) in Waldenstrom's Macroglobulinemia.. Blood, 2004, 104, 4929-4929.	1.4	2
309	CHOP Plus Rituximab (CHOP-R) in Waldenstrom's Macroglobulinemia (WM).. Blood, 2004, 104, 4930-4930.	1.4	1
310	A Novel Murine Model for Human Waldenstrom's Macroglobulinemia.. Blood, 2004, 104, 3646-3646.	1.4	0
311	Polymorphisms in the Hyaluronan Synthase 1 Gene May Be Predisposing Factors for Waldenstrom's Macroglobulinemia.. Blood, 2004, 104, 1363-1363.	1.4	1
312	Induction of Multiple Myeloma-Specific Cytotoxic T Lymphocytes Using HLA-A2.1-Specific CD19 and CD20 Peptides.. Blood, 2004, 104, 2477-2477.	1.4	0
313	Mutator Genes UDG and AID Appear To Be Normal in Class-Switch Deficient and Clonally Homogeneous Waldenstrom's Macroglobulinemias Having Either Germline or Hypermutated Clonotypic IgH VDJ.. Blood, 2004, 104, 1359-1359.	1.4	0
314	Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 2003, 30, 127-131.	2.2	86
315	Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 2003, 30, 116-120.	2.2	304
316	Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 2003, 30, 121-126.	2.2	94
317	Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: Therapeutic applications and considerations. Seminars in Oncology, 2003, 30, 248-252.	2.2	33
318	Novel biologically based therapies for Waldenstrom's macroglobulinemia. Seminars in Oncology, 2003, 30, 309-312.	2.2	45
319	Defining Waldenstrom's macroglobulinemia. Seminars in Oncology, 2003, 30, 107-109.	2.2	21
320	Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 2003, 30, 110-115.	2.2	841
321	Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. British Journal of Haematology, 2003, 121, 592-596.	2.5	45
322	CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic Applications. Journal of Immunotherapy, 2002, 25, 72-81.	2.4	123
323	CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. Journal of Immunotherapy, 2001, 24, 272-279.	2.4	144
324	Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies. Journal of Immunotherapy, 2001, 24, 263-271.	2.4	188

#	ARTICLE	IF	CITATIONS
325	Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. <i>Blood</i> , 2001, 98, 210-216.	1.4	869
326	Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies. <i>Journal of Immunotherapy (1993-1997)</i> , 2001, 24, 263-271.	0.1	11
327	CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia. <i>Journal of Immunotherapy (1993-1997)</i> , 2001, 24, 272-279.	0.1	12
328	Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2000, 7, 126-132.	3.0	7
329	Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. <i>Oncogene</i> , 1997, 15, 837-843.	5.9	177
330	WALDENSTRÅM MACROGLOBULINEMIA/LYMPHOPLASMACYTIC LYMPHOMA. , 0, , 129-149.		0
331	Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. , 0, , 190-215.		0
332	Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma. , 0, , 138-154.		0
333	Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. , 0, , 207-227.		0